CCR

CC chemokine receptor (CCR) antagonists block G protein-coupled receptors that guide leukocyte migration. CCR2, a receptor for monocyte chemoattractant protein 1 (MCP-1), was cloned in 1994 as two splice variants. CCR5 was identified in 1996 as a fusion cofactor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1). Maraviroc, described in 2005 as a selective small-molecule CCR5 inhibitor, blocks this route of viral entry. Other CCR5 antagonists include vicriviroc malate and aplaviroc, while INCB3344 and MK-0812 target CCR2. Cenicriviroc blocks both CCR2 and CCR5, and GSK2239633A is a CCR4 antagonist for studies of T cell trafficking.

Items 101-115 of 115

  • CCR1 antagonist 13
    Cat. No.
    A59588

    CCR1 antagonist 13

    CCR1 antagonist 13 is a selective antagonist of the CCR1 chemokine receptor. This small molecule inhibitor effectively disrupts CCR1 signaling, making it a valuable tool for investigating the roles of CCR1 in inflammatory responses and immune cell migration. Its applications extend to research on autoimmune diseases, chronic inflammatory conditions, and the modulation of chemokine-mediated pathways.

    Out of stock

    All 3 sizes
  • SQA1
    Cat. No.
    A59591

    SQA1

    SQA1 is a squaramide derivative that functions as a CCR6 and CXCR2 antagonist, displaying a dissociation constant (Kd) of 250 nM. It effectively occupies the intracellular pocket, overlapping with the G protein binding site, which helps stabilize the closed conformation of the receptor. This compound is useful in research applications targeting chemokine receptor signaling pathways and their roles in inflammatory responses and immune cell trafficking.

    25 mg
    $2,285.00
    50 mg
    $2,935.00
    All 3 sizes
  • CCR2 antagonist 6
    Cat. No.
    A59592

    CCR2 antagonist 6

    CCR2 Antagonist 6 is a potent CCR2 antagonist with a Ki value of 0.215 μM for CCR2 and 0.174 μM for human CCR2B. This compound exhibits significant biological activity by inhibiting the CCR2 receptor, making it a valuable tool for studying inflammatory processes and autoimmune diseases. Its specificity and efficacy contribute to the understanding of CCR2-related pathways in various pathophysiological conditions.

    Out of stock

    All 3 sizes
  • CCR5 antagonist 5
    Cat. No.
    A59593

    CCR5 antagonist 5

    CCR5 antagonist 5 is an effective CCR5 antagonist that targets the CCR5 receptor, playing a critical role in modulating immune response and inflammation. This compound is particularly valuable for research applications focused on HIV infection and other viral pathogens, offering insights into therapeutic strategies for immunological disorders and viral disease management.

    25 mg
    $2,035.00
    50 mg
    $2,610.00
    All 3 sizes
  • trans-J-113863
    Cat. No.
    A59595

    trans-J-113863

    trans-J-113863 is a potent antagonist of the CCR1 and CCR3 chemokine receptors. It effectively inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants, exhibiting IC50 values of 9.57 nM and 93.8 nM, respectively. This compound serves as a valuable tool for research focused on inflammation and immune responses, offering insights into the roles of these receptors in various biological contexts.

    1 mg
    $65.00
    5 mg
    $175.00
    All 3 sizes
  • CCR8 antagonist 3
    Cat. No.
    A59596

    CCR8 antagonist 3

    CCR8 antagonist 3 is a selective antagonist of the CCR8 receptor, exhibiting an IC50 value of 0.062 µM. This compound demonstrates stability in human microsomes, making it suitable for various in vitro studies. Its potential applications include exploring mechanisms of immune response modulation and investigating therapeutic strategies for inflammatory diseases and cancer.

    Out of stock

    All 3 sizes
  • CP-865569
    Cat. No.
    A59599

    CP-865569

    CP-865569 is a potent CCR1 antagonist, specifically designed to inhibit the activity of the CCR1 chemokine receptor. This compound demonstrates potential therapeutic effects in the modulation of inflammatory responses, making it valuable for research into inflammatory and autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Its ability to selectively target CCR1 makes CP-865569 an important tool for investigating the roles of chemokines in disease pathology and therapeutic intervention.

    Out of stock

    All 3 sizes
  • BMS-457
    Cat. No.
    A59600

    BMS-457

    BMS-457 is a potent and selective antagonist of the chemokine receptor CCR1. This compound demonstrates significant biological activity in modulating inflammatory pathways and is primarily utilized in research applications related to rheumatoid arthritis. Its ability to inhibit CCR1 makes it a valuable tool for studying the role of chemokines in autoimmune disorders.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • SCH 350581
    Cat. No.
    A59602

    SCH 350581

    Synonyms: AD-101

    SCH 350581 is a CCR5 antagonist that effectively inhibits HIV-1 replication. By obstructing viral entry into host cells and preventing the binding of the gp120 protein to primary lymphocytes, SCH 350581 plays a critical role in studying HIV-1 pathogenesis and potential therapeutic interventions. This compound is valuable for research applications focused on antiviral drug development and the mechanisms of HIV entry.

    Out of stock

    All 3 sizes
  • AZ760
    Cat. No.
    A59603

    AZ760

    AZ760 is a potent antagonist of the CCR8 receptor, which plays a significant role in immune response modulation. This compound demonstrates excellent potency and favorable lipophilicity, resulting in a high free fraction in blood. However, it is important to note that AZ760 exhibits unacceptable inhibition of the hERG potassium channel, which may have implications for cardiovascular safety in therapeutic applications.

    25 mg
    $1,370.00
    50 mg
    $1,795.00
    All 3 sizes
  • CCR7 antagonist 1
    Cat. No.
    A59791

    CCR7 antagonist 1

    CCR7 antagonist 1 is a potent dual antagonist of CXCR2 and CCR7, exhibiting an IC50 of 11.02 μM for CXCR2 and 0.43 μM for CCR7. This compound demonstrates significant inhibition of chemokine receptor signaling, making it valuable for studying inflammatory responses and immune system modulation. Its application spans various fields, including cancer research and autoimmune disease studies, where targeting these receptors can provide insights into disease mechanisms and potential therapeutic strategies.

    5 mg
    $305.00
    10 mg
    $505.00
    All 4 sizes
  • SLW131
    Cat. No.
    A59844

    SLW131

    SLW131 is a potent CCR7 antagonist, demonstrating a high affinity with a Ki value of 9.85 nM. This compound effectively inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, as well as β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also disrupts CCL19-induced morphological alterations in primary bone marrow-derived dendritic cells and impedes CCR7-mediated migration in mouse CD4+ T cells, making it a valuable tool for research in immune response and cell signaling pathways.

    Out of stock

    All 3 sizes
  • AZD0233
    Cat. No.
    A64573

    AZD0233

    AZD0233 is an orally active antagonist of the chemokine receptor CX3CR1. By modulating the CX3CR1/CX3CL1 signaling pathway, AZD0233 exerts significant immunomodulatory effects. In preclinical studies, it has demonstrated the ability to enhance cardiac function while reducing macrophage infiltration and fibrotic scar formation in a murine model of dilated cardiomyopathy. This compound serves as a valuable tool for research into cardiovascular diseases, particularly in the context of dilated cardiomyopathy.

    1 mg
    $115.00
    5 mg
    $290.00
    All 6 sizes
  • Fosrugocrixan
    Cat. No.
    A64574

    Fosrugocrixan

    Fosrugocrixan is a potent antagonist of the CX3C chemokine receptor 1 (CX3CR1), known for its significant anti-inflammatory effects. By inhibiting CX3CR1, Fosrugocrixan plays a crucial role in studying inflammatory diseases and related pathways. This compound is particularly valuable in research applications focused on chronic inflammatory conditions and immune response modulation.

    Out of stock

    All 3 sizes
  • JMS-17-2 hydrochloride
    Cat. No.
    A64575

    JMS-17-2 hydrochloride

    JMS-17-2 hydrochloride is a potent and selective antagonist of the CX3CR1 receptor, exhibiting an IC50 of 0.32 nM. This compound has been shown to impair metastatic seeding and colonization of breast cancer cells, making it a valuable tool for cancer researchers investigating metastasis and related pathways. Its specificity for CX3CR1 allows for targeted studies in various disease models.

    10 mg
    $805.00
    50 mg
    $3,215.00
    All 2 sizes

Items 101-115 of 115

Added to your cart

View Cart Checkout

    Loading...